In 2014, the journey of Xaga Surgical began with a critical moment in the career of urologist Andreas Forsvall. Two patients developed sepsis after prostate biopsies within a single week, prompting an investigation into the clinic's biopsy needle. It became clear to Dr Forsvall that the existing design posed a significant risk of transferring bacteria into sterile tissue. Surprisingly, there were no alternative needle designs available, and scientific literature offered no solutions. This discovery ignited a mission to create a safer needle design and marked the birth of Xaga Surgical. Prototypes were made and subsequent rigorous testing, studies and refinement validated the technology's effectiveness, setting the stage for Xaga Surgical to revolutionize both infection prevention and cancer diagnostics. Our innovative approach reduces bacterial transfer in biopsies by 96%1, while aiming to significantly enhance precision in cancer diagnostics. Additionally, with the introduction of fluid and port needles, Xaga Surgical is ready to adress the problem of 3,4 million2 annual hospital acquired infections caused by needles.
Welcome to the future of medical needles, where Xaga Surgical aims to lead the way in infection prevention and cancer diagnostics. Elegantly transforming healthcare for the better.
Image shows the collection of fecal matter between needle parts in a tru-cut biopsy needle. The mechanical root cause of infections in transrectal prostate biopsy was discovered - the finding that sparked the founding of Xaga Surgical.
1 Forsvall A, Fisher J, Cardoso JFP, Wagenius M, Tverring J, Nilson B, Dahlin A, Bratt O, Linder A, Mohanty T. Evaluation of the Forsvall biopsy needle in an ex vivo model of transrectal prostate biopsy - a novel needle design with the objective to reduce the risk of post-biopsy infection. Scand J Urol. 2021 Jun;55(3):227-234. doi: 10.1080/21681805.2021.1921023. Epub 2021 May 17. PMID: 33999753.
2 Xaga Surgical estimate based on available scientific data
At Xaga Surgical, we've set our sights on addressing two crucial challenges in modern medicine: the prevalence of needle caused hospital-acquired infections and the need for enhanced cancer diagnostics.
By innovating and redefining a fundamental tool of medicine – the medical needle, we aim to make medicine safer and better. Our primary goal is to create medical needles that prioritize patient safety and ease for healthcare professionals while introducing exceptional total cost-effectiveness for users and society as a whole.
Annually, over 50 million individuals1 are needlessly exposed to health risks during needle punctures. Needle induced infections and suboptimal cancer diagnostis are incurring an estimated annual healthcare and public cost of $80 billion1. We firmly believe that the crux of this issue lies in needle design, and our technology stands as a rational solution.
Remarkably, to our knowledge, Xaga Surgical stands as the sole entity globally dedicated to addressing this pressing concern, underscoring the immense responsibility we bear for the future.
We work as hard as we can to get our products to market, to be able to start help preventing unnecessary infections and improve cancer diagnostics.
As we prepare to enter the global market, Xaga Surgical welcomes collaborations to ensure this life-saving technology reaches patients and healthcare providers worldwide.
1 Xaga Surgical estimate based on available scientific data
.PNG)